Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) fell 6.8% during trading on Monday . The stock traded as low as $14.40 and last traded at $14.43. 1,860,935 shares were traded during trading, an increase of 451% from the average session volume of 337,931 shares. The stock had previously closed at $15.49.
Silverback Therapeutics Price Performance
The firm's 50-day moving average is $13.93 and its 200 day moving average is $12.76. The stock has a market cap of $484.62 million, a price-to-earnings ratio of -5.55 and a beta of 0.60.
Silverback Therapeutics Company Profile
(
Get Free Report)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
See Also
Before you consider Silverback Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.
While Silverback Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
